CEO | BioCrux Consaltants FZE | UAE
Talal Alzaher has completed his PHD in Biological Chemistry in 1990 from Essex University/UK and postdoctoral studies from Essex University and Imparial Collge/UK. He worked almost 30 years in biopharma and bioindustry reserach and development leading roles, and now he is the founder and Managing Director of BioCrux Consultants specialied in regulatry development consualtations for Biopharma and biosmilars. He has published more than 29 papers in reputed journals and a regular speaker on biotech and biosimilars.
Director | Geropharm | Russian Federation
R&D Director of GEROPHARM establishing product development of the company’s portfolio.
Joined GEROPHARM as a head of clinical trials department in Oct 2016. Successfully performed several clinical trials including hyperinsulinemic euglycemic clamps and bioequivalence, Phase III trials. In Sept 2018 was appointed to R&D Director of GEROPHARM - CJSC “Pharm-Holding”.
Provides training for GCP, mentoring of R&D managers. Established Clinical Research Community in Saint Petersburg with monthly meetings for different aspects of clinical trials discussion.
Has more than 20 publications including international. Participated in international conferences as a speaker in Switzerland, Spain, Czech Republic, Netherlands, Turkey and other countries.
Director | Dubai Pharmacy College for Girls | UAE
With more than 20 years of teaching and research experience, Prof. Shahiwala is currently serving as a Professor in Department of Pharmaceutics and Program Director-Postgraduate studies at Dubai Pharmacy College, Dubai. Prof. Shahiwala received his masters and doctorate in pharmaceutics and pharmaceutical technology from The Maharaja Sayajirao University of Baroda, INDIA with high research output in the area of novel drug delivery. His Postdoctoral Research at Northeastern University, USA was specifically focused on applications of nanotechnology in the field of drug delivery and drug targeting. Prof. Shahiwala published several international publications in high impact peer reviewed journals, 8 book chapters and filed 2 patents. He is also an editor of three books with internationally renowned publishers. Prof. Shahiwala’s research credentials have established him as a chief editor, an editorial board member, a reviewer, a speaker and an invited author for various pharmaceutical scientific journals and conferences. Prof. Shahiwala also has more than 3 years of rich research experience in Formulation & Development Division of large scale manufacturers of Pharmaceuticals in India as an added technical expertise in his field. His current research interests are to integrate targeted nanocarriers with the traditional and biotechnology based medicines in treating chronic and infectious diseases and he wish to collaborate with industries for translating the developed projects into commercially viable products.
Director | Medicine for Europe | Belgium
Sergio Napolitano is Legal Affairs and Trade Director at Medicines for Europe. Before joining Medicines for Europe, Sergio Napolitano worked in the Directorate General for External Policies of the European Parliament where he was part of the Secretariat of the Committee on International Trade (INTA). In 2012, he authored a Report of the European Parliament on “The Role of the Congress in Shaping the US Trade Policy”. He previously worked in the Trade Policy Department of the Permanent Representation of Italy to the EU on multilateral, plurilateral and bilateral trade negotiations, EU investment policy and IPR. Sergio Napolitano is qualified for mediator certification in most American states. He holds a degree in Law from the University of Naples Suor Orsola Benincasa, an Erasmus Diploma at the Université ParisSorbonne, and a LL.M. on EU and European Public Law from the University College of London (UCL).
Biogen Biosimilars Leader | Ewopharma | Croatia
Sandra Simic is graduated pharmacist (University of Pharmacy and biochemistry Zagreb, Croatia) and holds MBA postgraduate diploma from Cotrugli Business School. She started her career in pharmaceutical industry 12 years ago, and has been in charge of several positions included project management and key account management. She has extensive experience in marketing and sales of original biologics (adalimumab and vedolizumab) in European markets. Currently she works as Biogen Biosimilars Leader in company Ewopharma which is representative partner for Biogen biosimilars program in central and eastern Europe– and is responsible for commercial operations of 3 Biogen TNF-? inhibitors in Croatian market.
Biosimilars Consulting CH | Switzerland
An M.D. licensed in Nuclear Medicine working 20 years in Pharma Industry, 14 as Global Medical Executive for Biosimilars. Expertise in delivering customised Biosimilar concepts globally.
Pharmaceutical Executive with nearly 20 years of industry experience in Big Pharma and start up environments. Significant experience working in matrix and non-matrix organizations, setting up projects and new platforms/units within companies (Megatrials, Biosimilars Business Unit and Biosimilars Platform) in different regions of the world (EU, USA/Canada and Asia). Profound strategic/operational/scientific and project management expertise and skills. Excellent technical knowledge and track record of innovation in strategy, operations and project management, clinical study designs, patient recruitment strategies, and integration of Market Access and Clinical Research.
CEO & Founder | RegenerAge Clinic | USA
Dr. Osorio is an innovative businessman with an distinct entrepreneurial mindset concentrated adding value on areas of Biotechnology (mRNA), Reprogramming & Regenerative Medicine for translational use in humans and a variety of clinical applications aimed for both the private and the public health sectors. He is the CEO of RegenerAge Clinic and RegenerAge Beauty. VP and Clinical Developer for Bioquark,Inc. CCO at Reanima Advance Biosciences Project. CEO at Dr. Jois® and BiorganicAging®. Medical Advisor at The Cracking Monkey® and HairLogica®. CMO at What Skin Needs™/WSN International Pty. Ltd. Executive VP and Chairman of the WAMS Americas Division. Earned MD degree at Westhill University
Dean | MAHSA University | Malaysia
Prof. Dr. Nahlah Elkudssiah Ismail graduated with a bachelor’s Degree in pharmacy (Hons) from Universiti Kebangsaan Malaysia in the year 2000 and successfully awarded a PhD degree in the field of clinical pharmaceutics at Institute of Pharmaceutical Innovation (IPI) and School of Pharmacy, University of Bradford, Bradford, United Kingdom (UK) in July 2005. To date, she has taught more than 50 courses to diploma, degree and postgraduate students in UK and Malaysia. As the pioneer of clinical pharmaceutics in Malaysia, she is the founder of the first Clinical Pharmaceutics Research Group (CPRG) (2008) in Malaysia and that was later acknowledged as Clinical Biopharmaceutics Research Group (CBRG) under Research Initiative Group (RIG) by Research Management Institute (RMI), UiTM. She holds membership in various local and international pharmacy and health-based organizations. Prof. Dr. Nahlah had published more than 200 publications including research journal articles, proceedings, chapters in books, books and magazine. She has been invited to deliver lectures and conduct workshops at local and international events as well as a reviewer for local and international journals. Prof. Dr. Nahlah had been awarded research and travel grants as well as awards and medals in national and international scientific invention, innovation and design exhibitions, competitions and conferences. As a registered senior clinical pharmacist and a teacher-practitioner, she was one of the regular invited guests for radio UFM Malaysia under segment “U & Health” covering numerous health topics as well as one of the invited speakers for leadership and soft skills development. She is a Council Member of Malaysian Academy of Pharmacy since January 2018. Holding various posts at different management level at different institutions, currently, Prof. Dr. Nahlah is the Deputy Dean of Academic and Operations at the Faculty of Pharmacy, MAHSA University, Bandar Saujana Putra, Selangor, Malaysia.
I have been working in bioprocessing for developing biosimilars using yeast cells and mammalian cells as expression systems at MINAPHARM pharmaceuticals for 8 years. I am currently holding the following titles of Head of the yeast & mammalian cell culture upstream department, in addition to being the project manager for bioprocess technology transfer to external parties. I have experience in developing different types of recombinant molecules; hormones, anticoagulants & monoclonal antibodies.
Professor | Beni Suef University | Egypt
Prof. Abd El-Latif Hesham, Professor of Microbial Genetics and Environmental Meta-Genome Biotechnology, Genetics Department, Faculty of Agriculture, Beni Suef University, Egypt. He graduated and got his M.Sc from Genetics department, Faculty of Agriculture, Assiut University, Egypt and his PhD degree from Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences in "Microbial Genetics and Environmental Meta-Genome Biotechnology". He awarded postdoctoral studies about " Meta-Genome Biotechnology" from CAS-TWAS. In 2017, he got an appointment as Professor for Environmental Meta-Genome Biotechnology. He has co-authored more than 80 peer-reviewed publications. He interesting in “Microbial Genetics & Biotechnology”, “Biodegradation, Bioremediation & Phytoremediation”, " Microbial community structure and Enzyme activities”, “Soil Microbiology”, “Biological Control”, “Anti-microbial activates”, “Biofertilizer”, “Biofuels” and "Environmental Meta-Genome Biotechnology". Prof. Hesham serves as an associate editor and editorial board member for international reputed journals such as, Scientific Reports (A Nature Publishing Group Journal, impact factor 5.078); Frontiers in Microbiology (A Nature Publishing Group Partner-Frontiers Journal, impact factor 4.072); Frontiers in Plant Science ( impact factor 4.298); PeerJ (impact factor 2.18); Current Bioinformatics (Bentham Science, impact factor 1.726), International Journal of Agriculture & Biology (impact factor 0.902); Journal of Environmental Biology (impact factor 0.56); Genetics and Molecular Research (Impact factor 0.764).
Director | Govt Affairs&Policy Biosimilars | Switzerland
Senior Director Government Affairs and Policy Biosimilars Switzerland